South Korea's Ministry of Food and Drug Safety approves Arena Pharmaceuticals' (ARNA +3.9%) weight loss drug Belviq. The product will be marketed in-country by Ildong Pharmaceutical Co. Ltd.The approval triggers a $3M milestone payment to Arena from Ildong.Bevliq will be manufactured at Arena's Switzerland facility and sold to Ildong at 35% of its annual net sales. This will increase on a tiered basis up to 45% on the portion of net sales exceeding $15.0M.
No hay mejores mercados que el surcoreano? Allí están todos a arroz no creo que suban apenas las ventas. A ver si se animan con otros mercados mucho más sujerentes como el Europeo. Al menos ingresan 3M$ algo es algo.
ARNA